Trial Profile
A Randomized, Double-Blind, Placebo-Controlled 12-Week Study to Determine the Efficacy of EPA+DHA (SC401B) on Hypertriglyceridemia (TG ≥ 500 mg/dL and ≤ 2000 mg/dL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid/docosahexaenoic acid (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Sancilio & Company
- 22 Nov 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as study never initiated. IND placed on Hold
- 14 Dec 2015 New trial record